1 / 8

Medivir at the Carnegie Lunch: Stabilizing Business and Future Revenues

Read about Medivir's strategic moves in therapeutic areas, partnership structures, and revenue sources. Explore upcoming trials, operational focus, and potential acquisitions for 2008.

djorgensen
Download Presentation

Medivir at the Carnegie Lunch: Stabilizing Business and Future Revenues

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. The presenters from Medivirat the Carnegie lunch January 21 Lars Adlersson CEOProf Bertil Samuelsson, VP Discovery and ResearchRein Piir, CFO / IR

  2. Stabilizing the business by entering new therapeutic areas 2 2 3 3 3 1 2 2 1 1 1 1 1 1 1 2 1 2 3 3 1 2 1 2 1 2 2 1 2 1 2 1 2 2 2 3 • 90% of 2007 deal value is linked to protease based projects • 100% of internal resources are invested in protease based projects, Lipsovir being the only exception Lipsovir Protease based Polymerase based (HIV Franchise & HCV Pol)

  3. Stabilizing the business by adding a mix of partnership structures

  4. Future potential sources of revenues Existing license agreements Potential new license agreements Pharma Sales QUID(S) HEPATITIS C PI (TMC 435350) LIPSOVIR HIV PI MIV 701 & new cathepsin K inhibitors CO-PROMOTION ACQUISITIONS HIV Franchise Partners Late Discovery Projects (COPD ) Other Discovery Projects (BACE, Renin and cathepsin S) Future revenues will be used to finance operations towards profitability and to build pharma sales

  5. PipelineJanuary 2008

  6. TMC4353350 - Phase IIa Clinical Trial • The OPERA-1 trial will assess the number of patients that achieve RVR (undetectable virus at week 4) • The OPERA-1 trial will be able to assess number of patients achieving SVR (after 4 weeks of combo therapy plus 24 or 48 weeks of IFN plus RBV) • The Phase IIa RVR data available already H1 2008, will initiate the design and start of the phase IIb trial (OPERA-2) • Statement - There is a place for next generation HCV PI like TMC435350 with: • High potency – low drug load • Once-daily – good compliance resulting in increased efficacy • Large forgiveness factor – higher efficacy • Less side effects – possible from shorter duration of treatment • More treatment options – exclude ribavarin from therapy

  7. Operational focus and activities 2008 1(2) LIPSOVIR • First to prevent outbreaks of cold sores? • Phase III results available late Q1 2008 • Partnering discussions ongoing • The aim is to have the commercial strategy, including • partner/s in place by the end of 2008 • First regulatory approval is expected H1 2009 • Phase Ib completed with excellent results – to be presented • in April • Phase IIa initiated – results will probably be presented in Q4 • Phase IIb could start before year end HEPATITIS C (TMC-435350) • Broad preclinical program – follow-on candidate drug • to be selected during the spring • The partnering process will be initiated shortly CATHEPSIN K (MIV-701) COPD, Renin, BACE etc • Evaluate interest for broad partnerships

  8. Operational focus and activities 2008 2(2) • Portfolio sourcing exercise has begun • Co-marketing discussions with a few selected companies initiated • Infrastructure can be put in place with short notice PHARMA SALES • Two phase IIb trials with Valomaciclovir recently initiated • Head-to-head vs market leader for shingles – once daily vs three times daily • and for the treatment of acute infectious mononucleosis • Chinese condom coating initiative well underway HIV FRANCHISE • Cash end-of 2007 ~SEK 370m • Substantially lower expenses level (appr. SEK 190m) during 2008 • Future revenues will be used to extend runway and build • pharma sales FINANCE

More Related